Literature DB >> 11270656

Structure-activity relationships for six ketolide antibiotics.

W S Champney1, C L Tober.   

Abstract

Six structurally related 3-keto-substituted macrolide antibiotics (ketolides) were compared for concentration-dependent inhibitory effects on growth rate, viable cell number, and protein synthesis rates in Staphylococcus aureus cells. Inhibitory effects on 50S ribosomal subunit formation were also examined, as this is a second target for these antibiotics. A concentration range of 0.01 to 0.1 microg/ml was tested. An IC50 for inhibition of translation and 50S synthesis was measured for each compound, to relate structural features to inhibitory activity. ABT-773 was the most effective of the six compounds tested with an IC50 = 0.035 microg/ml. HMR 3004 was almost as effective with an IC50 = 0.05 microg/ml. Two 2-fluoroketolides (HMR 3562 and HMR 3787) were equivalent in their inhibitory activity with an IC50 = 0.06 microg/ml. Telithromycin (HMR 3647) had an IC50 = 0.08 microg/ml, and HMR 3832 was least effective with an IC50 = 0.11 microg/ml. Each antibiotic had an equivalent inhibitory effect on translation and 50S subunit formation. These results indicate specific structural features of these antimicrobial agents, which contribute to defined inhibitory activities against susceptible organisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270656     DOI: 10.1007/pl00021055

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  11 in total

1.  30S ribosomal subunit assembly is a target for inhibition by aminoglycosides in Escherichia coli.

Authors:  Roopal Mehta; W Scott Champney
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Astonishing diversity of natural surfactants: 4. Fatty acid amide glycosides, their analogs and derivatives.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

3.  Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W Scott Champney; Ward K Rodgers
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

Review 4.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.

Authors:  Ward Rodgers; Ashley D Frazier; W Scott Champney
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

7.  The Use of Ketolides in Treatment of Upper Respiratory Tract Infections.

Authors:  George G. Zhanel; Aleksandra K. Wierzbowski; PhD Hisanaga; Daryl J. Hoban
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

8.  Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives.

Authors:  Zhonghui Zheng; Deping Du; Lili Cao; Jun Liu; Xiaofang Chen
Journal:  J Antibiot (Tokyo)       Date:  2016-04-27       Impact factor: 2.649

9.  Impact of ribosomal modification on the binding of the antibiotic telithromycin using a combined grand canonical monte carlo/molecular dynamics simulation approach.

Authors:  Meagan C Small; Pedro Lopes; Rodrigo B Andrade; Alexander D Mackerell
Journal:  PLoS Comput Biol       Date:  2013-06-13       Impact factor: 4.475

10.  Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.

Authors:  George G Zhanel; Tamiko Hisanaga; Aleksandra Wierzbowski; Daryl J Hoban
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.